VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

ECTRIMS 2021 | Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, talks on complement inhibition as an exciting therapeutic approach in relapsing anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Eculizumab, a C5-targeting recombinant monoclonal antibody (mAb), was approved by the EMA and FDA for the treatment of AQP4-positive NMOSD in adult patients in 2019, making it the first approved therapy in this setting. The approvals were based on the findings of the pivotal Phase III PREVENT trial, which randomized patient 2:1 to receive fortnightly intravenous eculizumab or placebo. At 48 weeks, over 95% of patients in the eculizumab arm were relapse free, compared to 45% in the placebo arm; an affect maintained to the 144-week assessment. Dr Oreja-Guevara comments on the promise of eculizumab in this space. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.

Disclosures

Celia Oreja-Guevara has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva.